drugset
drugset / Trial / NCT06737731

A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

NCT06737731 ↗

Phase 1/2 Recruiting 300 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.

Timeline

Start
2025-01-21
Primary completion
2026-11
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1681 Unknown — —

Indications

cancer